Efficacy of Four Drug Regimens for Preventing Malaria in Senegalese Children
Author Information
Author(s): Sokhna Cheikh, Cissé Badara, Bâ El Hadj, Milligan Paul, Hallett Rachel, Sutherland Colin, Gaye Oumar, Boulanger Denis, Simondon Kirsten, Simondon François, Targett Geoffrey, Lines Jo, Greenwood Brian, Trape Jean-François
Primary Institution: Institut de Recherche pour le Développement, Dakar, Senegal
Hypothesis
Is the SP+3AQ regimen more effective than other regimens in preventing malaria in children?
Conclusion
Monthly treatment with SP+3AQ is highly effective for seasonal malaria prevention and minimizes drug resistance.
Supporting Evidence
- The SP+3AQ group had the lowest incidence of malaria at 4.9%.
- The study included 2020 children who were treated and followed up.
- The SP+3AQ regimen was twice as effective as the previously used SP+1AS regimen.
Takeaway
This study tested different medicines to see which one works best to stop kids from getting malaria, and found that one combination worked really well.
Methodology
An open-label trial comparing four treatment regimens in 2020 children aged 6–59 months.
Potential Biases
Potential bias due to non-random allocation and lack of blinding.
Limitations
The trial was not blinded, which may have influenced reporting of adverse events.
Participant Demographics
Children aged 6–59 months, with a mean age of 32 months, 49% male.
Statistical Information
P-Value
0.006
Confidence Interval
95% CI 0.30–0.81
Statistical Significance
p=0.006
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website